Yuanyuan Wang

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study

J. Flamm, W. Spreen, L. Mena, 2022, Journal of the International AIDS Society.

Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)

J. Flamm, W. Spreen, L. Mena, 2022, Journal of the International AIDS Society.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

S. Swindells, Kimberly Smith, H. Crauwels, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.